As the field of peptide receptor radionuclide therapy is expanding and other targeted radionuclide therapies are on their way in less-rare cancer types, as for example 177Lu- prostate-specific-membrane-antigen targeting prostate-specific-membrane-antigen in metastatic prostate cancer, the frequency of this rare and possibly fatal subacute side effect might increase in the coming years. Here, FOLH1 is linked to metastatic prostate carcinoma.